188 related articles for article (PubMed ID: 25193277)
1. Mesothelin expression is associated with poor outcomes in breast cancer.
Li YR; Xian RR; Ziober A; Conejo-Garcia J; Perales-Puchalt A; June CH; Zhang PJ; Tchou J
Breast Cancer Res Treat; 2014 Oct; 147(3):675-84. PubMed ID: 25193277
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin expression and survival outcomes in triple receptor negative breast cancer.
Parinyanitikul N; Blumenschein GR; Wu Y; Lei X; Chavez-Macgregor M; Smart M; Gonzalez-Angulo AM
Clin Breast Cancer; 2013 Oct; 13(5):378-84. PubMed ID: 23810431
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers.
Bayoglu IV; Kucukzeybek BB; Kucukzeybek Y; Varol U; Yildiz I; Alacacioglu A; Akyol M; Demir L; Dirican A; Yildiz Y; Salman T; Tarhan MO
Biomed Pharmacother; 2015 Mar; 70():190-5. PubMed ID: 25776500
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
5. MALAT-1: LncRNA ruling miR-182/PIG-C/mesothelin triad in triple negative breast cancer.
Barsoum FS; Awad AS; Hussein NH; Eissa RA; El Tayebi HM
Pathol Res Pract; 2020 Dec; 216(12):153274. PubMed ID: 33171372
[TBL] [Abstract][Full Text] [Related]
6. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
[TBL] [Abstract][Full Text] [Related]
7.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
8. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
[TBL] [Abstract][Full Text] [Related]
9. Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.
Lamberts LE; de Groot DJ; Bense RD; de Vries EG; Fehrmann RS
Oncotarget; 2015 Sep; 6(29):28164-72. PubMed ID: 26172299
[TBL] [Abstract][Full Text] [Related]
10. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival.
Tozbikian G; Brogi E; Kadota K; Catalano J; Akram M; Patil S; Ho AY; Reis-Filho JS; Weigelt B; Norton L; Adusumilli PS; Wen HY
PLoS One; 2014; 9(12):e114900. PubMed ID: 25506917
[TBL] [Abstract][Full Text] [Related]
12. The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer.
He M; Zhang JX; Jiang YZ; Chen YL; Yang HY; Tang LC; Shao ZM; Di GH
Oncotarget; 2017 Jul; 8(27):44870-44880. PubMed ID: 28496004
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
Breast Cancer Res Treat; 2017 Jan; 161(2):279-287. PubMed ID: 27888421
[TBL] [Abstract][Full Text] [Related]
14. CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
Pedersen MH; Hood BL; Ehmsen S; Beck HC; Conrads TP; Bak M; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2019 Feb; 144(3):631-640. PubMed ID: 30110125
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
Mitra D; Bhattacharyya S; Alam N; Sen S; Mitra S; Mandal S; Vignesh S; Majumder B; Murmu N
Breast Cancer Res Treat; 2020 Jan; 179(2):359-370. PubMed ID: 31686261
[TBL] [Abstract][Full Text] [Related]
16. Association between mesothelin expression and survival outcomes in patients with triple-negative breast cancer: a protocol for a systematic review.
Wang M; Li A; Sun G; Mbuagbaw L; Reid S; Lovrics PJ; Thabane L
Syst Rev; 2016 Aug; 5(1):133. PubMed ID: 27514374
[TBL] [Abstract][Full Text] [Related]
17. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
[TBL] [Abstract][Full Text] [Related]
18. Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study.
Tinholt M; Garred Ø; Borgen E; Beraki E; Schlichting E; Kristensen V; Sahlberg KK; Iversen N
J Thromb Haemost; 2018 Jul; 16(7):1347-1356. PubMed ID: 29766637
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival.
Michaelidou K; Ardavanis A; Scorilas A
Breast Cancer Res Treat; 2015 Jul; 152(2):323-36. PubMed ID: 26099606
[TBL] [Abstract][Full Text] [Related]
20. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
